[go: up one dir, main page]

HUP9802961A2 - Kötési partner ciklinfüggő kinázok inhibitoraihoz és ezek alkalmazása inhibitorok kereséséhez, valamint egy betegség diagnózisához vagy terápiájához - Google Patents

Kötési partner ciklinfüggő kinázok inhibitoraihoz és ezek alkalmazása inhibitorok kereséséhez, valamint egy betegség diagnózisához vagy terápiájához

Info

Publication number
HUP9802961A2
HUP9802961A2 HU9802961A HUP9802961A HUP9802961A2 HU P9802961 A2 HUP9802961 A2 HU P9802961A2 HU 9802961 A HU9802961 A HU 9802961A HU P9802961 A HUP9802961 A HU P9802961A HU P9802961 A2 HUP9802961 A2 HU P9802961A2
Authority
HU
Hungary
Prior art keywords
inhibitors
therapy
deseases
cyclin
exploring
Prior art date
Application number
HU9802961A
Other languages
English (en)
Inventor
Andrea Bürgin
Martin Eilers
Hans-Harald Sedlacek
Original Assignee
Hoechst Marion Roussel Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Marion Roussel Deutschland Gmbh filed Critical Hoechst Marion Roussel Deutschland Gmbh
Publication of HU9802961D0 publication Critical patent/HU9802961D0/hu
Publication of HUP9802961A2 publication Critical patent/HUP9802961A2/hu
Publication of HUP9802961A3 publication Critical patent/HUP9802961A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/635—Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)

Abstract

A találmány őlyan fehérjével főglalkőzik, amely a p27 cellűlárisfehérjét gátőlja, és ezáltal felfüggeszti a sejtek bűrjánzásának p27által végzett gátlását, főglalkőzik tővábbá ennek a fehérjénekdőminánsan közreható jellegű műtánsaival, a fentieknek megfelelőfehérjéket kódőldó nűkleinsavakkal, tővábbá ezeknek a fehérjéknek ésnűkleinsavaknak az alkalmazásával betegségek megelőzéséhez ésterápiájáhőz. A találmány feltár őlyan, a nevezett nűkleinsavakattartalmazó nűkleinsav-kőnstrűkciókat, amelyek betegségekgénterápiájáhőz alkalmazhatók. ŕ
HU9802961A 1997-12-20 1998-12-18 Binding partners for cyclin-dependent kinase-inhibitors, use thereof for exploring of inhibitors of deseases, for diagnostic and therapy HUP9802961A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19756975A DE19756975A1 (de) 1997-12-20 1997-12-20 Bindungspartner für Inhibitoren von cyclinabhängigen Kinasen und ihre Verwendung zur Suche nach Inhibitoren, zur Diagnose oder zur Therapie einer Erkrankung

Publications (3)

Publication Number Publication Date
HU9802961D0 HU9802961D0 (en) 1999-02-01
HUP9802961A2 true HUP9802961A2 (hu) 1999-07-28
HUP9802961A3 HUP9802961A3 (en) 2000-04-28

Family

ID=7852804

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9802961A HUP9802961A3 (en) 1997-12-20 1998-12-18 Binding partners for cyclin-dependent kinase-inhibitors, use thereof for exploring of inhibitors of deseases, for diagnostic and therapy

Country Status (15)

Country Link
US (1) US6265562B1 (hu)
EP (2) EP0926236A1 (hu)
JP (2) JPH11308997A (hu)
KR (2) KR19990063284A (hu)
CN (2) CN1225367A (hu)
AR (2) AR016436A1 (hu)
AU (2) AU758030B2 (hu)
BR (2) BR9805151A (hu)
CA (2) CA2255143A1 (hu)
CZ (2) CZ422598A3 (hu)
DE (1) DE19756975A1 (hu)
HU (1) HUP9802961A3 (hu)
ID (2) ID21582A (hu)
PL (2) PL330451A1 (hu)
TR (2) TR199802649A3 (hu)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19751587A1 (de) * 1997-11-21 1999-07-29 Hoechst Marion Roussel De Gmbh Onkogen- oder virusgesteuerte Expressionssysteme
GB9727512D0 (en) * 1997-12-31 1998-02-25 Adprotech Plc Fuzzy genes and their application in molecular adjuvants
DE19831420A1 (de) * 1998-07-14 2000-01-20 Hoechst Marion Roussel De Gmbh Expressionssysteme enthaltend chimäre Promotoren mit Bindungsstellen für rekombinante Transkriptionsfaktoren
GB0008582D0 (en) * 2000-04-08 2000-05-31 Adprotech Plc DNA immunization vectors
GB0025229D0 (en) * 2000-10-14 2000-11-29 Adprotech Ltd Veterinary immunisation vectors
AU2002365889A1 (en) * 2001-11-29 2003-06-17 Institutes For Pharmaceutical Discovery, Llc Regulated expression of recombinant dna
JP5976986B2 (ja) * 2005-10-01 2016-08-24 チャールズ スタウト， 調節可能な融合プロモーター
CN102016045A (zh) 2007-05-02 2011-04-13 梅瑞尔有限公司 具有改善的表达和稳定性的dna质粒
WO2011119920A2 (en) 2010-03-25 2011-09-29 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
CA2832109C (en) 2011-06-10 2021-07-06 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
EP2568289A3 (en) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
EP2679596B1 (en) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 env glycoprotein variant
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3069730A3 (en) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
JP2020511951A (ja) * 2017-01-03 2020-04-23 バイオアトラ、エルエルシー 老化細胞の処置のためのタンパク質療法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0455424A3 (en) * 1990-05-02 1992-04-29 Merck & Co. Inc. Mammalian inducible promoter cascade system
US5866755A (en) * 1993-06-14 1999-02-02 Basf Aktiengellschaft Animals transgenic for a tetracycline-regulated transcriptional inhibitor
US5464758A (en) * 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
GB9506466D0 (en) 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
DE19524720A1 (de) 1995-07-12 1997-01-16 Hoechst Ag Zellspezifische Gentherapie mit Hilfe eines neuen Promotors für den "Tissue Inhibitor of Metalloproteinasn-3"
DE19605279A1 (de) 1996-02-13 1997-08-14 Hoechst Ag Zielzellspezifische Vektoren für die Einschleusung von Genen in Zellen, Arzneimittel enthaltend derartige Vektoren und deren Verwendung
DE19605274A1 (de) 1996-02-13 1997-08-14 Hoechst Ag Nukleinsäurekonstrukte für die zellzyklusregulierte Expression von Genen, derartige Konstrukte enthaltende Zellen sowie deren Verwendung zur Herstellung von Heilmitteln
DE19751587A1 (de) * 1997-11-21 1999-07-29 Hoechst Marion Roussel De Gmbh Onkogen- oder virusgesteuerte Expressionssysteme

Also Published As

Publication number Publication date
BR9805152A (pt) 2000-03-21
EP0926237A2 (de) 1999-06-30
HU9802961D0 (en) 1999-02-01
CZ422598A3 (cs) 1999-07-14
AU758030B2 (en) 2003-03-13
KR19990063284A (ko) 1999-07-26
EP0926236A1 (de) 1999-06-30
AR017887A1 (es) 2001-10-24
BR9805151A (pt) 2000-03-21
TR199802648A2 (xx) 1999-07-21
TR199802649A2 (xx) 1999-07-21
AU747246B2 (en) 2002-05-09
PL330452A1 (en) 1999-06-21
CA2255143A1 (en) 1999-06-20
TR199802648A3 (tr) 1999-07-21
JPH11308997A (ja) 1999-11-09
CA2255141A1 (en) 1999-06-20
KR19990063285A (ko) 1999-07-26
AU9720598A (en) 1999-07-08
ID21582A (id) 1999-06-24
AR016436A1 (es) 2001-07-04
US6265562B1 (en) 2001-07-24
EP0926237A3 (de) 2000-01-05
HUP9802961A3 (en) 2000-04-28
TR199802649A3 (tr) 1999-07-21
JPH11313686A (ja) 1999-11-16
AU9720498A (en) 1999-07-08
CZ422398A3 (cs) 1999-07-14
DE19756975A1 (de) 1999-06-24
ID21534A (id) 1999-06-24
CN1225367A (zh) 1999-08-11
PL330451A1 (en) 1999-06-21
CN1227871A (zh) 1999-09-08

Similar Documents

Publication Publication Date Title
HUP9802961A2 (hu) Kötési partner ciklinfüggő kinázok inhibitoraihoz és ezek alkalmazása inhibitorok kereséséhez, valamint egy betegség diagnózisához vagy terápiájához
HUP0001293A1 (hu) Heterociklusos vegyületek és ezeket tartalmazó gyógyászati készítmények béta-amiloid-peptidek gátlására
EA199700135A1 (ru) Ингибиторы клеточной адгезии
HUP0000810A2 (hu) Esszenciális aminosavakat nagy mennyiségben tartalmazó fehérjék
HUP0001931A2 (hu) Kémiai vegyületek
HUP9902698A2 (hu) Humán bikunin
HUP0003533A2 (hu) Interleukin-18-at kötő fehérjék, előállításuk és alkalmazásuk
DE69738581D1 (de) Menschliche dnase i hyperaktive varianten
DK1005540T3 (da) IKK-beta-proteiner, nukleinsyrer og fremgangsmåder
ATE215125T1 (de) ßHEAT SHOCKß-PROTEINE UND BEHANDLUNG VON TUMOREN
BR9805544C1 (pt) Uso de um composto.
HUP0001014A2 (hu) Gasztrointesztinális lipáz inhibitorok felhasználása
WO2000015826A3 (en) Leptin induced genes
NO972391D0 (no) 2-substituerte 1,2,5-tiadiazolidin-3-on 1,1-dioksider og preparater og metoder for anvendelse derav
IT8468281A1 (it) Proglumide e composizioni farmaceutiche che la contengono per l'impiego nella terapia di affezioni neoplastiche.
DE69736276D1 (de) Menschliche dnase resistent gegen actininhibitoren
MX9702776A (es) Proteinas de proteasa de pulgas, moleculas de acido nucleico, y usos de las mismas.
HUP9800613A2 (hu) Humán Fas-antigén elleni humanizált antitest
FR2724320B1 (fr) Nouvel implant pour le traitement des maladies acquises
WO1998024887A3 (en) Parasitic nematode transglutaminase proteins, nucleic acid molecules, and uses thereof
NO995692D0 (no) Nye BPC-peptidsalter med organbeskyttende aktivitet, metoden for deres fremstilling og deres anvendelse
NO884324D0 (no) Fremgangsmaate til fremstilling av reninhemmende peptider og deres anvendelse.
WO1998020034A3 (en) Novel serine protease inhibitor nucleic acid molecules, proteins and uses thereof
DK0811068T3 (da) Humane DNase I varianter
HUP0100132A2 (hu) A béta-lipotropin és felhasználása